Tag: Sciences

BUFFALO, NY – The University at Buffalo's Center for Integrative Global Biomedical Sciences (CIGBS) has become a member of the Abbott Pandemic Defense Coalition, the industry's first global public health and health science coalition dedicated to early detection and response. soon in the future pandemic. threats

As part of the coalition, Gene Morse, PharmD, professor emeritus of pharmaceutical practice at SUNY US School of Pharmacy and Pharmaceutical Sciences, will be the principal investigator, providing expertise and conducting research to expand testing capacities and initiatives. Education on coalition sites.

The Abbott Pandemic Defense Coalition was formed to identify, detect, analyze and test emerging global threats, including variants of COVID-19. As Director of CIGBS and Co-Director of the Institute for Global Health at the State University of New York, Morse will work with a network of more than 20 scientific, academic and public health organizations on five different continents to build a network of "Frontline". . “Monitoring infrastructure for emerging and existing virus threats, including:

• Discover and track new pathogens and analyze how known viruses are changing
• Providing and sharing sequencing data to determine if a virus is a known or unknown pathogen
• Do follow-up testing to understand how many people have contracted the virus, where it has spread, and possible risk factors.
• Rapid development and implementation of diagnostic tests, if necessary using first case studies
• Educate the next generation of epidemiologists and virus hunters to be prepared for future pandemic threats

"This is a great opportunity to join other CIGBS efforts, including the Global Viral Network (GVN), and share the years of experience of our UB team mentors with a coalition of young scientists from different countries," Morse said.

Morse is also the principal investigator of several programs funded by the National Institutes of Health (NIH) Fogarty International Center, including the US-Zimbabwe HIV Training Program and the UB-West Indies Global Infectious Disease Research Training Program. He is also the primary mentor to two NIH Fogarty Emerging Global Leader Award winners in South Africa and Nigeria. CIGBS is a global center of excellence in virus control with sister centers in Jamaica, Trinidad and Tobago and Zimbabwe. "We plan to bring our integrated biomedical science model to Abbott's pandemic defense coalition and establish new partnerships with GVN centers and capacity-building programs such as FIC initiatives," says Morse.

"Global collaboration is needed more than ever to help us prepare for and prevent future virus outbreaks," said Gavin Cloherty, Ph.D., director of the Coalition and Abbott's head of infectious disease research. "UB's addition to the Abbott Pandemic Coalition will help train a new generation of young scientists and build strong capacity at new evidence-based surveillance sites in low- and middle-income countries to stay ahead of the next virus threat."

"UB's anticipated role in the coalition is excellent recognition of the high-quality programs and interdisciplinary approach that CIGBS fosters in its global research initiatives," said Gary Pollock, Ph.D., Dean of UB College of Pharmaceuticals.

Other university professors who have contributed to CIGBS' growing expertise on emerging pathogens include Andrew Talal, Timothy Murphy, Stanley Schwartz, John Tomaszewski, Oscar Gomez, Mark Hikar and Amy Jacobs, all from the School of Medicine and Jacobs Biomedical Sciences. ; Brian Tsuji, Qing Ma, Raymond Cha, and Robin DiFrancesco, all from the College of Pharmacy and Pharmaceutical Sciences; and Troy Wood and Paras Prasad from the College of Arts and Sciences.

Opportunities and perspectives in the field of mechanical engineering

Go to Life Sciences, Inc. If you want to know who controls (NASDAQ: ACHV ), you'll have to look at the composition of its stock register. With a 56% stake, individual investors own the majority of the company's shares. In other words, the group faces most of the upside potential (or downside risk).

Institutions in turn represent 43% of the company's shareholders. Large companies tend to have institutions as shareholders and we often see insiders owning shares in smaller companies.

Let's dive into each type of owner at Achieve Life Sciences, starting with the table below.

See our latest analysis of Achieve Life Sciences

What does institutional ownership tell us about outcomes in the life sciences?

Institutional investors often compare their returns to the returns of an index they typically track. Therefore, they often consider buying larger companies included in the standard.

As you can see, institutional investors have a large stake in Achieve Life Sciences. This may indicate that the company has some credibility in the investment community. However, it is best to avoid trusting institutional investors in the supposed validation that comes with it. Sometimes they are even wrong. It is not unusual to see a sharp drop in the stock price if two large institutional investors try to sell a stock at the same time. So it's worth taking a look at Achieve Life Sciences' past earnings history (below). Of course, keep in mind that there are other factors to consider.

Hedge funds do not own many shares of Achieve Life Sciences. Our records show that B. Riley Capital Management, LLC is the largest shareholder with a 20% stake. By comparison, the second and third largest shareholders own approximately 7.6% and 3.1% of the shares.

Based on our ownership data, 25 major shareholders collectively own less than 50% of the share register, meaning that no one person owns a controlling interest.

the story continues

While it makes sense to look at data on a company's institutional ownership, it also makes sense to look at analyst sentiment to see which way the wind is blowing. Few analysts cover stocks, so you can analyze the projected growth quite easily.

Achieve primary life sciences property

The definition of inside information can be subjective and varies by jurisdiction. Our data reflect individual insider information, capturing at least board members. Management is ultimately accountable to the board of directors. However, it is not uncommon for managers to be board members, especially if they are founders or CEOs.

Most view insider ownership as positive because it can indicate that the board is well connected to other stakeholders. However, sometimes too much power accumulates within this group.

Our most recent data shows that board members own less than 1% of Achieve Life Sciences, Inc. Board members appear to own no more than $883,000 in stock in the $104 million company. Many small business investors prefer to see a larger investment chart. You can click here to see if these experts are buying or selling.

general public property

The general public, consisting primarily of individual investors, collectively owns 56% of Achieve Life Sciences' stock. This level of ownership gives traditional investors some power to change key policy decisions, such as board composition, executive compensation and dividend payout rates.

Next steps:

It is always useful to think about the different groups that own shares in a company. But to better understand Achieve Life Sciences, we need to consider many other factors. Please note that Achieve Life Sciences shows 4 warning signs in our investment analysis , 2 of which should not be ignored…

If you're like me, you may wonder if this business will grow or shrink. Fortunately, you can check out this free report that shows analysts' predictions for the future.

NOTE: The figures in this article are calculated using data for the last twelve months, covering the 12-month period ending on the last day of the month following the balance sheet date. This may not be consistent with the reported data for the full year.

Have an opinion on this article? Worried about content? Contact us directly. You can also email the editorial staff at (at)Simplywallst.com.

This article on Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodologies and our articles are not intended to be financial advice. It is not a recommendation to buy or sell shares and does not take into account your financial objectives or situation. Our goal is to provide focused long-term analysis based on fundamental data. Please note that our analysis may not take into account recent company forecasts based on price or quality data. Simply Wall St has no position in the stocks mentioned.

Participate in a paid user research session
You'll receive a $30 Amazon gift card for one hour of your time, which will help us create better investment vehicles for individual investors like you. register here

Glendale, CA-based utility Titan is nearing an initial public offering

NexPoint, a billion-dollar alternative investment firm, has proposed plans to build a 200-acre, 4 million-square-foot life sciences facility in Plano on the former Electronic Data Systems campus. Called the TxS (Technology x Science) District, the project is centered around the 91-acre main campus and another 109 acres in the adjacent Legacy District.

The first and second phases of the campus will consist of four construction phases and include 970,000 square feet of labs and offices along with 120,000 square feet of office space. Initial plans for the site also include a community park, an amphitheater and a connection to the nearby Legacy commercial development.

NexPoint, which bought the main campus in 2018 and the surrounding land since then, is looking to build the campus through a public-private partnership. "This project will not only be a major economic catalyst for the region, but will also establish North Texas as a leader in the life sciences," said James Dondera, founder and director of NexPoint.

Architectural engineering and construction studio CRB International is collaborating on the project. JLL is in talks with NexPoint to become the leasing agent for the project.

"The TxS project will be unique in its ability to support life sciences companies at every stage of the process: discovery, early development and commercialization," says JLL's Matt Daniels. "With state-of-the-art research facilities, new federal policies that favor drug repatriation, and a tight labor market at coastal biomedical centers, Plano is poised to become a top choice for companies looking for expansion and solutions."

Flowserve agrees to acquire Velan for $245 million

In an all-cash deal, Dallas-based flow control products provider Flowserve has agreed to acquire Velan, an industrial valve maker, for $245 million. The transaction consists of $209 million of Velan's issued and outstanding equity capital and $36.3 million of total outstanding debt. Flowserve will also receive $31.4 million in free cash from Velan.

Velan, which has 1,650 employees in nine countries, reported revenue of $380 million for the 12 months ending November 2022. Upon completion of the transaction, Velan will become part of Flowserve's Flow Controls division. Within two years of closing, Flowserve expects to earn $20 million in operating cost synergies.

"We are very excited to have Whelan and his talented team join the Flowserve family," said Scott Rowe, Flowserve President and CEO. "With its strong position in the nuclear, refrigeration, industrial and defense markets and a highly complementary product portfolio, the addition of Velan contributes to our diversification, decarbonisation and digitalization strategy."

Mi Cocina is expanding with M Crowd in Houston

In May 2022, Edgar Guevara, CEO of M Crowd Restaurant Group, told the CEO of D Corporation that Mi Cocina was looking to expand into Houston. Now with 22 Mi Cocina locations in Texas and Oklahoma and a 23rd in McKinney this spring, M Crowd is officially expanding its exclusive Tex-Mex location in Houston.

The new restaurant is expected to open next October and create 80 to 100 new jobs.

Since March 2018, when Guevara took over as CEO of M Crowd Restaurant Group, the company's revenue has grown from $1 million to $1.5 million annually. Looking to the future, Guevara said his goal is to open two Mi Cocina's a year and expand into more national markets.

"Once we have a significant number of years, we can do more," says Guevara. “I think our product will do really well [in Houston]. And our real estate model also says that Denver and Atlanta are ready for development. There are smaller cities, but our model is to try to build four or five .Houston, build a big aircraft carrier there, and then go to another big market."

A new $125 million manufacturing facility is opening in Midlothian

SunOpta, a publicly traded Minneapolis vegetable company, has opened a new, 285,000-square-foot, $125 million manufacturing facility in Midlothian. The new plant will create about 175 new jobs.

The enterprise will produce a full line of dairy and non-dairy spreads, tea and other products. The new facility, the largest in the company's portfolio, will serve as a driving force for the company to achieve its goal of doubling its factory business by 2025 as it has nearly $200 million of investment in new manufacturing capacity at its facility.

The factory can expand to 400,000 square feet.

The plant footprint will reduce more than 15 million freight miles annually, and the company says the plant will reduce carbon emissions by 59 million pounds. In addition, the facility has installed water reuse equipment that can save up to 20 million gallons of water annually, an energy-efficient HVAC system that reduces energy use by 45%, and LED lights and water heaters that reduce energy use by 95% . %. %. . , offices and laboratories built with at least 40 percent recyclable materials.

writer

Ben Swanger is the editor-in-chief of D CEO , the professional publication of D Magazine . Ben runs the Dallas 500 team monthly…

Practical: Alumni Symposium | Sydney Gross Symposium

The MarketWatch news department was not involved in the creation of this content.

Feb. 09, 2023 (The Expresswire) – "Analysis of the impact of COVID-19 on the industry will be added to the final report."

Global "Life Sciences Market" 2023-2028 provides comprehensive and high-quality information on innovative business growth strategies, macro and micro economic factors, trend assessments and key players' economic statements. This report (107 pages) provides a major roadmap of recent growth opportunities from major key players, as well as future business perspectives and developments. This report provides detailed information about the company as well as business plans and new investment ideas in all regions such as North America, Asia and Europe. In addition, Life Sciences market report provides share estimates as well as CAGR status, revenue growth data, industry size and segment analysis.

মার্কেটওয়াচ নিউজ এই তৈরির সাথে সাথে জড়িত নান

2022

Bangor – Bay University is pleased to offer a number of Health Science degrees. The course starts on February 27.

Health science is a relatively new academic discipline, according to an article in US News. Although many universities do not have well-established health science programs, there are many reasons to consider pursuing a health science degree.

1. Start working quickly in various medical professions

Health sciences focus on health issues rather than basic sciences (such as biology or chemistry). This reassignment broadens students' understanding of many areas of health care.

Left to right: Gary Tischler and Richard Coles of the Vanburton Group together at 3 West 29th Street (Getty, Vanburton Group, Google Maps)

One of New York's most anticipated office projects certainly seems to be changing.

The VanBurton Group is considering developing its vacant lot next to Marble Collegiate Church at West 29th Street and Fifth Avenue as a life sciences project rather than an office tower, according to a person familiar with the matter. When finished, it will be one of the largest projects in the city.

The latest attack on the site comes more than seven years after the community formed a joint venture with Jill Feldman's firm HFZ Capital, which originally designed the 64-story residential tower at 3 West 29th Street next to the historic church at 272 Fifth Ave.

By 2019, HFZ had moved into a 34-story office tower called 29 and 5 and designed by Bjarke Ingels. Soon after, the Zona Franca's multibillion-dollar real estate portfolio began to collapse due to a wave of loans and foreclosures.

Van Burton, the intermediate lender on the project, relinquished its interest in the joint venture and acquired the site in 2021. It appears to be primarily promoting plans for an office tower. It hired the architectural firm Kohn Pedersen Fox, designers of the ultra-tall SL Green One Vanderbilt, and construction was scheduled to begin last year.

But VanBurton hasn't submitted a plan since then and the job remains open. The source said it could build a life sciences project on the land immediately and the site could be used by local hospitals.

A potential shift toward life sciences looms as the Manhattan office market suffers from low demand. Some office owners want to convert their properties into living space, but the process can be expensive and not suitable for all buildings.

Life science is one of the most popular sectors of real estate. About 20 million square feet of space is expected to be offered to life sciences tenants this year, according to a report by Cushman & Wakefield.

New York lags other cities like Boston and San Francisco in life sciences construction, but Taconic Partners is renovating a vacant 400,000-square-foot building into a life sciences research facility at 125 West End Avenue.

The Nomad site was an innovative development in the Hamria Free Zone. The Marble Collegiate Church, founded in 1628, is one of the oldest Protestant denominations in the country. Best known for Pastor Norman Vincent Peale, author of The Power of Positive Thinking, the church once counted Donald Trump among its members.

Investor filings show the projected cost of the planned HFZ project is $1.3 billion as of 2019, and the church plans to use development funds to restore the existing 1851 building and build a public facility at the base of the new tower. Now you probably won't have any involvement in the project.

Van Burton declined to comment.

Today, early detection of cancer is much more common than it was ten years ago. Exact Sciences ( NASDAQ:EXAS ) can't claim all the credit, but the non-invasive cancer tests it sells play an important role. About 4 million people will be screened for cancer by the company in 2021.

Despite its product's large audience, Exact Science's shares have fallen nearly 40% in the past year and are still below their peak of 56% in early 2021. Risky for most investors. Here's what you need to know.

Reasons to buy stocks in sound science

Exact Sciences introduces ColoGuard, a non-invasive colon cancer screening. It continues to channel Cologuard's revenue into innovative new cancer detection methods, including multiple cancer early detection (MCED) tests for the general public. Success in the highly sought-after MCED arena could push this stock higher, and Exact Sciences continues to move forward.

Last September, a blood test that tested 1,132 samples for four different cancer markers found that 61% of the samples had cancer. It is not very sensitive, but the lack of false positives is very reassuring. Exact Sciences also reported a specificity rate of 98.2%, meaning that almost all reported samples actually came from people with known cancer.

Exact Science's flagship test, ColorGuard, will soon receive an update called ColorGuard 2.0. In early 2022, the company tested samples from the Deep-Sea trial that led to the initial approval of ColoGuard using ColoGuard 2.0, and the results were very encouraging.

Investors worry about potential competition from Guardian Health 's ( NASDAQ:GH ) blood-based Shield test Fortunately for the exact science, last December's Shield test produced disappointing results that strongly suggest Cologuard 2.0 wins.

Reasons to be cautious

Sound science knows how to sell millions of cancer tests, but monetizing them is another story. The company continues to invest heavily in new initiatives such as the MCED program, which has not been successful. As a result, the company has been facing huge losses in recent quarters.

© YCharts EXAS Net Income (Quarterly)

Young companies in the high growth phase often lose money trying to gain market share. Unfortunately, the exact science of cancer screening is stagnant. In the third quarter of 2022, the company's flagship cancer screening screened 960,000 people, just 10,000 more than the previous year.

Why now?

Exact Sciences is far from its previous peak, but there is still plenty of optimism at current prices. The stock is currently selling at 6 times. This is a relatively low figure for Exact Science, but surprisingly high compared to its larger rivals Quest Diagnostics and LabCorp , which trade at 1.7x and 1.6x sales, respectively.

Across different tests, Exact Sciences should maintain higher rates than LabCorp or Quest. Unfortunately, staying ahead of the competition requires such large investments that the company believes it won't be able to report adjusted earnings until the third quarter of 2023. In accordance with generally accepted accounting principles.

Brand loyalty is low in the diagnostic industry. Doctors usually choose the best test based on clinical trial data. Cologuard has done well, but it's always a matter of time before a good mousetrap is made. So I would not buy Exact Science or any other diagnostics company that is not already in steady growth in profits.

Sponsor:

10 stocks we love more than exact science

When our team of award-winning analysts have stock advice, it's worth listening. After all, the Motley Stock Advisor newsletter has doubled the market they've been operating for over a decade*.

They've just revealed what they think are the ten best stocks investors can buy right now…and exact science isn't one of them. That's right, they think these 10 stocks are a good buy.

Check out 10 promotions

* Stock advisor returns on January 9, 2023

Corey Renauer has no positions in any of the listed stocks. The Motley Fool has a position and recommends Guardian Health. The Motley Fool recommends Exact Sciences and Quest Diagnostics. Motley Fool has a disclosure policy.

"The Bloody Fall of the 90s and 80s Cycles, Harry Dent, Crypto Interview

As 2023 begins, following a trend professionals in The Woodlands, Texas and the greater Houston area are just beginning to see, some are seeing a number of announcements from companies relocating or expanding their presence in the region, including some from California.

According to the Woodlands Area Economic Development Partnership, as of 2019, The Woodlands saw changes across employment sectors as energy companies reduced their presence or moved out of the area and healthcare employment increased as businesses expanded.

Economic experts in the region note that these factors, as well as factors such as a favorable business environment, have increased the attractiveness of the region for many foreign companies, especially in the life sciences sector.

A 2022 study by Stanford University's Hoover Institution found that at least 132 businesses moved from California to Texas in 2018-21.

That's more than four times the second-highest number of actions in California, Tennessee, which had 31 corporate actions.

Gil Staley, chairman of The Woodlands Area EDP, said interest from science and technology companies is creating new businesses in the area that George Mitchell and The Woodlands founders originally envisioned for such companies.

"We see this as a rebirth of the research forest [corridor]," Staley said.

In 2022, two California life sciences companies announced they will relocate their headquarters or establish a presence in The Woodlands.

Cellipont Bioservices, which develops and manufactures cell therapies for other companies, opened a 76,000-square-foot manufacturing facility in November at 9501 Lakeside Blvd.

Work also began in late December on a suite for Nurix Therapeutics at 8800 Technology Forest Place as part of a larger life science complex.

Joel Marcus, CEO and founder of Alexandria Real Estate Equities Inc., the California-based company developing the complex, said the campus will be about 318,000 square feet when complete.

The first phase will be completed in the first quarter of 2023.

"There will be nothing like this in Houston, on a uniquely safe and accessible campus," Marcus said.

field of life sciences

In an area once home to energy companies like Anadarko, the energy sector's share of non-retail jobs among large employers has fallen from 27% to 8% since 2019. By the beginning of 2022, healthcare accounted for more than 30%. According to The Woodlands Area EDP.

This growth in health care is part of what makes the region attractive for life sciences, said Kathy Pryor, chief development officer and senior vice president of membership for the Greater Houston Partnership, the region's future events hub.Houston Dec. 12. 13.

"Increased interest in economic development in the region, particularly in Montgomery County, has recently created tremendous opportunities for innovation and growth in the industrial and technology sectors," Pryor said at the event.

California-based companies have taken note, and Deborah Wilde, president and CEO of Cellipont, said The Woodlands is a good fit for the company, both financially and logistically.

"We did a regional analysis … and found that economically the wooded area is a great location for workers," Wilde said. "When schools are good, staff stay longer. This is a beautiful and safe place."

Stella Vnuk, Cellipon's chief scientific officer, said the area is ideal for companies like Cellipon because of its proximity to the Texas Medical Center and Houston-area airports, as well as its growing scientific research and innovation community.

Texas is also a central location within the country and an important factor in the rapid transport of sensitive biological materials over long distances.

"A lot of innovation is coming from the Texas region. … It is very important for us to further develop and expand cell therapy in this very important region,” said Vnuk.

Wilde said the company has 70 employees in San Diego, and although some executives will relocate, most of the new hires will be local. Once fully completed, he plans to add a manufacturing component to the site, which will employ about 200 people, he said.

A larger complex is planned for the Technology Forest location, formerly occupied by Lexicon Pharmaceuticals and moving to Technology Forest Boulevard.

The former 260,000-square-foot campus will be transformed into a life sciences campus that will offer more than 300,000 square feet of office and laboratory space, as well as meeting rooms, a fitness center and courts, according to Sarah Kabakoff. . . Vice President of Strategic Communications, Alexandria.

“We chose The Woodlands to redesign and develop a unique, mission-critical, multi-tenant, co-working campus under the Alexandria brand that will bring to the Houston area market a highly convenient and secure workspace for the first time: a vibrant environment for life. sciences and other advanced technology companies, Marcus said in an email.

The first company to announce plans to lease space in the area is San Francisco-based Nurix Therapeutics. According to The Woodlands Area EDP, the company held a groundbreaking ceremony for the project on December 13. According to Alexandria, the company is working on protein modulation for cancer treatment. The company will operate its own research and development facility in the country.

national interests

Jim Carman, president of The Howard Hughes Corp.'s Houston region, said 33 businesses plan to relocate or expand within their leases in The Woodlands by 2020, representing more than 500,000 square feet of office space and 2,000 new residents. works. after.

Howard Hughes leases space on the 31st and 32nd floors of The Woodlands Towers to The Waterway, formerly Anadarko Towers, which it purchased in late 2019.

The tower at 9950 Woodloch Forest Drive will house several new corporate headquarters or offices, including Obagi Cosmeceuticals, which is moving from California, and Centric Infrastructure Group, which is moving from The Woodlands. New York cryptocurrency firm NYDIG is also setting up office space there.

"Over the past few years, we've definitely seen a diversification of our client organizations," Carman said. "One of the most interesting ones is really some of the companies in the renewable business space."

These companies include Lancium Technologies, which is moving from Texas to an entire floor of The Woodlands Towers in 2022. The company works with renewable energy infrastructure and technology.

Other tech companies moving from The Woodlands include SmartDraw Software, which is moving from California to Hughes Landing in 2022, and chemicals and pharmaceuticals company SI Group, which is moving from New York in the fall, according to Howard Hughes Of.

Although many companies are moving to remote work, the need for office space is still great, Carman said. Office leasing in The Woodlands was more resilient than in the greater Houston area during the third quarter, with The Woodlands having a 23.3% vacancy rate of 16.6%, according to real estate brokerage Colliers.

Businesses moving to The Woodlands are also drawn to the community's proximity to jobs and services, he said.

"These companies' real estate needs haven't changed significantly. They need the same square footage," Karman said. “The difference is more focus on comfort. When our employees come to the office, we give them more reasons to be there than just a paycheck and a desk.

Prepare future employees

Companies moving to The Woodlands will primarily hire locally, Staley said.

"They want to see a very well-trained workforce to hire," Staley said.

According to the Census Bureau's 2021 American Community Survey Five-Year Estimates, 64.3 percent of Woodlands residents age 25 and older have a bachelor's degree or higher, compared to the national average of 33.7 percent.

According to him, the presence of companies in new fields, such as life sciences, can also help advance educational programs.

Staley said EDP plans to begin discussions with the Lone Star College System in early 2023 to discuss life science programs.

LSCS deputy director Linda Head said plans could include courses for medical labs and production technicians, as well as cleanroom courses and continuing education for employees.

"We're working very quickly to design the right programs and labs and change what we need to be ready in about six months," Head said.

US Navy SEAL videos leaked